CBD, a Drug Worth Researching
- Jeremy Garner
- Nov 10, 2020
- 2 min read
January 18, 2020
Currently, the FDA has only approved one cannabis-based drug, Epidiolex to treat childhood epilepsy syndromes.
That hasn’t stopped many consumers from purchasing CBD as an over-the-counter treatment to alleviate minor medical conditions such as headaches or pain.
As research continues, many medical professionals believe CBD could become a medical breakthrough that could replace dozens of traditional drugs on the market.
Dr. David Dawit, Chief Scientific Officer at Eos Scientific explains that…
“While those in the industry, medical professionals and the public all seem to be in favor of CBD as a medical product, the stringent regulatory barriers in place before any product can be fully licensed require, quite rightly, extensive testing and trials.”
There are several ways to ingest medicinal CBD: tinctures, topicals, oils, and more. Recently GB Sciences obtained a patent for their oral thin films.
The films are gaining popularity because of their efficiency, convenience, and discreteness.
“This is great for patients, who have access to an entirely new way to consume precisely-dosed cannabis without the potential drawbacks of other delivery systems,” Chief Executive Officer and Chairman of GB Sciences Inc.
John Poss said, “And nobody else has this technology – making it a good mechanism for GB Sciences to further monetize its considerable intellectual property portfolio.”
While CBD on its own is not approved for drug use Amarantus Bioscience Holdings subsidiary, Elto Pharma received notice from the European Patent Office that they can use CBD and other chemical compounds along with eltoprazine and eltoprazine in the treatment of Parkinson’s disease and Parkinson’s disease levodopa-induced dyskinesia.
The study involving 22 subjects for Eltoprazine showed that it significantly reduced peak dose dyskinesia with no major adverse effects reported.
Comments